Optimizing feasibility through increased data collection.
Industry provides endless methods in crafting solutions for patients.
Explore the pivotal role of Next-Generation Sequencing (NGS) panel customization in driving advancements in oncology research.
Recent study results highlight need for new metrics in ECOG scoring to mitigate variability.
A data-fueled framework for sponsors and CROs in navigating this shifting terrain.
New requirements must be put in place to ensure data quality and integrity.
The role of the clinical research associate may be key in addressing challenges around the adoption of digital tools.
How one CRO in India quickly implemented processes and technology to mitigate risk
Many companies have implemented new technologies and are adopting clinical trial models that are more patient-centric.
Monday, October 25, 2021 at 10am EDT Attend this webinar to hear about CGP, the latest in onco-innovation for genomic biomarker testing and uncover the role that Illumina and Q2 Solutions are playing in evolving the CGP testing landscape to deliver a localized testing model to support oncology precision medicine clinical trials in Europe. Lastly, the webinar will reveal the updated roadmap of Q2 Solutions’ Edinburgh Genomics laboratory.
Push for accurate data collection during pandemic led by increased focus on patient engagement.
Study evaluates the use of AI-supported medical coding module.
To have a successful integration of data from across clinical systems, a strong understanding of the data is a critical.
Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Industry must work closely with patients to advance the use of decentralized technology.
Fostering common eConsent terminologies enriches communication and understanding across all stakeholders.
Laboratory services organization focuses on easing patient and site burden with improved collection device.
Sponsors need to develop a strategy on how to evaluate the impact of the pandemic on the re-start of halted trials.
COVID-19 speeds up clinical research and creates new advancements within industry.
Survey taken by CROs and pharma/biotech companies seeks answers in maximizing partnership.
A discussion of the regulatory history behind audit trails and its interpretation as it relates to clinical research data originating or residing in EDC or eCOA systems.
How pharmaceutical start-ups can mitigate risk and avoid costly hiring mistakes.
Master protocols helped accelerate research during the pandemic in the EU. How can US companies learn from this and start preparing master protocols now?
How can managers ensure their clinical trial participants represent future patients?
Looking beyond regulatory compliance.
2020 Tufts CSDD – IBM Watson Health benchmarking study highlights need for new functionality from EDC solutions and providers.
Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.
In light of Facebook ban on ads targeting patients, industry has chance to reinvent digital advertising for trials.